Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pregnancy folic acid therapy

The folic acid group of vitamins was recognized by various effects on several test organisms. The simplest active member may be considered to be pteroylglutamic acid or folacin. This may be combined with extra molecules of glutamic acid. Experimental production of a deficiency of these factors has not been reported in man, but the anemia of certain diseases of man responds to folacin therapy. These diseases include sprue, megaloblastic anemia of infancy, nutritional macrocytic anemia, and the pernicious anemia of pregnancy. Folic acid is involved in some way with the metabolism of amino acids. [Pg.229]

Methotrexate, an antimetabolite, is indicated for moderate to severe psoriasis. It is particularly beneficial for psoriatic arthritis. It is also indicated for patients refractory to topical or UV therapy. Methotrexate can be administered orally, subcutaneously, or intramuscularly. The starting dose is 7.5 to 15 mg per week, increased incrementally by 2.5 mg every 2 to 4 weeks until response maximal doses are approximately 25 mg/wk. Adverse effects include nausea, vomiting, mucosal ulceration, stomatitis, malaise, headache, macrocytic anemia, and hepatic and pulmonary toxicity. Nausea and macrocytic anemia can be ameliorated by giving oral folic acid 1 to 5 mg/day. Methotrexate should be avoided in patients with active infections and in those with liver disease. It is contraindicated in pregnancy because it is teratogenic. [Pg.206]

Since sulfasalazine inhibits the absorption of folic acid, patients may become folate deficient during longterm therapy. Sulfasalazine decreases the bioavailabiUty of digoxin. Cholestyramine reduces the metabolism of sulfasalazine. Sulfasalazine causes a reversible decrease in sperm counts. Sulfasalazine is safe in pregnancy. [Pg.480]

Hyperhomocysteinemia also has been implicated as a risk factor for other complications of pregnancy, including intrauterine growth retardation, eclampsia, birth defects other than neural tube defects, and premature separation of the placenta from the wall of the uterus. It is not yet known, however, whether treatment with folic acid or other homocysteine-lowering therapies will protect pregnant women from these complications. [Pg.232]

Like oral iron, parenteral iron is used too widely. When iron is truly needed, oral administration is generally preferable (9). Intractable gastrointestinal intolerance to oral formulations, hyperemesis in pregnancy, very severe blood loss, and possibly ulcerative colitis are some of the few valid indications for parenteral iron. A low ironbinding capacity (for example due to prior saturating iron therapy or malnutrition), folic acid deficiency, and an allergic constitution predispose the patient to adverse reactions to parenteral iron. Iron injections have been reported to provoke hemolytic anemia in cases of paroxysmal nocturnal hemoglobinuria. [Pg.1911]

A deficiency of folic acid results in the development of a megaloblastic anemia and more rarely neuropathy. The deficiency may result from a reduced intake, an increased demand (e.g., pregnancy), abnormal metabolism, or as a result of various drug therapies. [Pg.256]

Folic acid deficiency can occur due to pregnancy, malabsorption syndromes or inadequate diet. Some drugs, for example phenytoin (used in epilepsy), oral contraceptives and isoniazid (used in treating tuberculosis), can cause reduced absorption of folic acid. Oral replacement therapy with folic acid is effective. [Pg.74]

Carbamazepine should, if at all possible, not be administered, particularly during the first three months of pregnancy. Regardless of a change in therapy, administration of folic acid before and during the gestational period, and of vitamin K in the last trimester, may be useful in protecting the mother and fetus. [Pg.37]

Citrovorum factor stimulates hematologic improvement, similar to that induced by folic acid, in sprue, nutritional macrocytic anemia, macrocytic anemia of pregnancy, pernicious anemia and megaloblastic anemia of infancy. Whether this factor is more active than folic acid has not been determined. Neither folic acid nor citrovorum factor will prevent hematologic relapse or the development of neurologic lesions in pernicious anemia. Folic acid is helpful at times in the therapy of macrocytic anemia associated with cirrhosis of the liver. [Pg.570]


See other pages where Pregnancy folic acid therapy is mentioned: [Pg.596]    [Pg.292]    [Pg.138]    [Pg.216]    [Pg.140]    [Pg.354]    [Pg.288]    [Pg.146]    [Pg.1113]    [Pg.259]    [Pg.567]    [Pg.575]   
See also in sourсe #XX -- [ Pg.1822 ]




SEARCH



Folic

Folic acid

Folic acid therapy

Pregnancy folic acid

© 2024 chempedia.info